The characteristic of solifenacin and fesoterodine with
regard to their clinical efficacy, tolerability and safety
in the treatment of overactive bladder
Article published in Urologia Polska 2008/61/4.
Andrzej Wróbel1, Tomasz Rechberger1, Paweł Kieres2
- 1II Klinika Ginekologii Uniwersytetu Medycznego w Lublinie
2Oddział Urologiczny im. ¦w. Rafała, Wojewódzki Specjalistyczny Zespół Opieki Zdrowotnej GruĽlicy i Chorób Płuc w Kielcach
urinary bladder solifenacin fesoterodine overactive bladder pharmacotherapy
- Antimuscarinics such as solifenacin or fesoterodine achieve a good balance of efficacy and tolerability and as a consequence are associated
- with good long-term patient satisfaction. The therapeutic profile however may differ because various antimuscarinic drugs have
- different affinity to the five subtypes of muscarinic receptors that represent targets for OAB treatment (mainly M2 and M3). Because
- of the lack of head-to-head randomized double-blinded, placebo-controlled studies we tried to perform indirect comparison of these
- two new-generation antimuscarinics with regard to their efficacy, tolerability and safety in the OAB treatment.
- Kelleher CI, Cardozo I, Chapple CR et al: Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005, 95, 81-85.
- Cardozo L, Lisec M, Millard R et al: Randomized, double blind placebo controlled trial of the once daily antimuscatinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172, 1919-1924.
- Brunton S, Kuritzky L: Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 2005, 21, 71-80.
- Chapple CR, Rechberger T, Shukri S et al: Randomized, doubleblind placebo and tolterodine-controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93, 303-310.
- Abrams P, Swift S: Solifenacin is effective for the treatment of OAB dry patients; a pooled analysis. Eur Urol 2005, 48, 483-487.
- Chapple CR, Martinez-Garcia R, Selvagii L et al: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005, 23, 25-34.
- Haab F, Cardozo I, Chapple C, Rider AM: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005, 47, 376-384.
- Kreder K, Mayne C, Jonas U: Long-term safety, tolerability and efficacy of extended -release tolterodine in the treatment of overactive bladder. Eur Urol 2002, 41, 588-595.
- Abrams P, Malone – Lee J, Jacquetin B: Twelve – month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001, 18, 551-560.
- Appell RA, Abrams P, Drutz HP et al: Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001, 19, 141-147.
- Cole P: Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004, 29, 715-720.
- Postlind H, Danielson A, Lindgren A: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998, 26, 289-293.
- Sachse R, Cawello W, Haag MC: Dose – proportional pharmacokinetics of the new antimuscarinic fesoterodine. Naunyn-Schmied Arch Pharmacol 2003, 367, 115.
- Cawello W, Auer S, Hammes W: Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002, 365, 110.
- Nitti V, Wiatrak M, Kreitman L, Lipsitz D: Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Paper presented at International Continence Society, Montreal, Canada, August 31 – September 2, 2005.
- Chapple Ch, Kerrebroeck P, Tubaro A et al: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007, 52, 1204-1212.
- Nitti V, Dmochowski R, Sand P, Forst H-T: Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007, 178, 2488-2494.
- van Kerrebroeck P, Kreder K, Jonas U et al: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urol 2001, 57, 414.
- Rovner ES, Wein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002, 41, 6.
- Van Kerrebroeck P, Kreder K, Jonas U et aler N, Wein A; on behalf of the Tolterodine Study Group: Tolterodine once daily: superior efficacy
- and tolerability in the treatment of the overactive bladder. Urol 2001, 57, 414.
- Wagner TH, Hu TW, Bentkover J, LeBlanc K et al: Health – related consequences of overactive bladder. Am J Manag Care 2002, 8, 598-607.
- Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. BJU Int 2007, 100, 987-1006.
II Klinika Ginekologii
ul. Jaczewskiego 8
tel. kom. 691 376 307